688428 诺诚健华
已收盘 12-31 15:00:01
资讯
新帖
简况
诺诚健华(09969)授出140万份受限制股份单位
智通财经 · 17:18
诺诚健华(09969)授出140万份受限制股份单位
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
国元国际：给予诺诚健华(09969)目标价16.81港元 评级“买入”
智通财经 · 12-24
国元国际：给予诺诚健华(09969)目标价16.81港元 评级“买入”
诺诚健华宣布获得NMPA批准，开展Tyk2抑制剂ICP-488治疗皮肤性狼疮的二期临床试验
美股速递 · 12-23
诺诚健华宣布获得NMPA批准，开展Tyk2抑制剂ICP-488治疗皮肤性狼疮的二期临床试验
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
时代财经 · 12-22
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验
智通财经 · 12-19
港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验
奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察
华夏时报网 · 12-18
奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察
诺诚健华宣布在中国获批新型Tyk2抑制剂Soficitinib用于慢性自发性荨麻疹的II/III期临床试验
美股速递 · 12-18
诺诚健华宣布在中国获批新型Tyk2抑制剂Soficitinib用于慢性自发性荨麻疹的II/III期临床试验
12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股
证券之星 · 12-16
12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股
创新药概念再度走低 诺诚健华(09969.HK)跌超5%
每日经济新闻 · 12-16
创新药概念再度走低 诺诚健华(09969.HK)跌超5%
诺诚健华：截至2025年11月28日A股股东户数约1.79万户
证券日报 · 12-15
诺诚健华：截至2025年11月28日A股股东户数约1.79万户
诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验
美股速递 · 12-14
诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验
诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点
智通财经 · 12-14
诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点
港股诺诚健华涨超3%
每日经济新闻 · 12-12
港股诺诚健华涨超3%
港股异动 | 诺诚健华(09969)涨超3% 预计不久将递交佐来曲替尼治疗儿童患者新药上市申请
智通财经网 · 12-12
港股异动 | 诺诚健华(09969)涨超3% 预计不久将递交佐来曲替尼治疗儿童患者新药上市申请
诺诚健华宣布宜诺凯（奥布替尼）新增适应症纳入2025年国家医保药品目录
证券日报 · 12-07
诺诚健华宣布宜诺凯（奥布替尼）新增适应症纳入2025年国家医保药品目录
诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%
证券之星 · 12-04
诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%
诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药
证券日报 · 11-29
诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药
诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售
每日经济新闻 · 11-28
诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售
诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症
美股速递 · 11-28
诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症
加载更多
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":20.52,"timestamp":1767164401000,"preClose":20.59,"halted":0,"volume":4782765,"delay":0,"changeRate":-0.0034,"floatShares":268000000,"shares":1764999999,"eps":-0.1302,"marketStatus":"已收盘","change":-0.07,"latestTime":"12-31 15:00:01","open":20.58,"high":20.79,"low":20.28,"amount":97778900,"amplitude":0.0248,"askPrice":20.52,"askSize":75,"bidPrice":20.51,"bidSize":146,"shortable":0,"etf":0,"ttmEps":-0.1302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":20.59,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":22.65,"lowLimit":18.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1764643952,"isCdr":false,"pbRate":5.43,"roa":"--","roe":"--","epsLYR":-0.26,"committee":-0.614845,"marketValue":36210000000,"turnoverRate":0.0178,"status":1,"afterMarket":{"amount":0,"volume":0,"close":20.52,"buyVolume":243,"sellVolume":0,"time":1767166437558,"indexStatus":"已收盘 12-31 15:30:00","preClose":20.59},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":12.3,"timestamp":1767154109009,"preClose":12.35,"halted":0,"volume":4001417,"delay":0,"premium":"-46.22"},"floatMarketCap":5507000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2595727116","title":"诺诚健华(09969)授出140万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2595727116","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595727116?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2025年12月31日，公司根据2023年股权激励计划授予两名承授人140万份受限制股份单位，相当于公司于本公告日期已发行股份总数的约0.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0239","688428","09969","BK1161"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["000661","LU2097828805.USD","LU2488822045.USD","BK1593","02142","688428","LU1997244956.HKD","01801","09995","01530","02509","LU2495084118.USD","LU1969619763.USD","600276","06978","01167","002755","BK0188","BK1161","BK0239","BK0028","BK0012","LU2148510915.USD","LU0405327148.USD","BK1589","688062","BK0060","BK0183","BK0057","LU1997245177.USD","02096","BK0196","LU2097828557.USD","LU1064130708.USD","LU2097828631.EUR","BK1574","LU1997245094.SGD","LU0502904849.HKD","LU1781817850.SGD","LU2580892862.HKD","03692","LU1146622755.USD","LU2097828474.EUR","LU2097828714.EUR","688331","LU1328615791.USD","LU1064131003.USD","603087","688336","LU0405327494.USD"],"gpt_icon":0},{"id":"2593342479","title":"国元国际：给予诺诚健华(09969)目标价16.81港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593342479","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593342479?lang=zh_cn&edition=full","pubTime":"2025-12-24 14:58","pubTimestamp":1766559522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国元国际发布研报称，预计诺诚健华2025-27年收入分别为人民币20.1亿、20.6亿、25.6亿元，净利润分别为人民币1.17亿、0.17亿、1.88亿元，公司持有现金及等价物约72亿元，现金足够进行创新研究。根据DCF模型，给予目标价16.81港元，给予买入评级，较现价有28%的升幅。CDE已批准启动奥布替尼治疗SLE的III期临床试验，预计2026年第一季度首例患者入组。Zenas支付1亿美元现金首付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","688428"],"gpt_icon":0},{"id":"1143469039","title":"诺诚健华宣布获得NMPA批准，开展Tyk2抑制剂ICP-488治疗皮肤性狼疮的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1143469039","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143469039?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:02","pubTimestamp":1766484152,"startTime":"0","endTime":"0","summary":"诺诚健华宣布获得NMPA批准，开展Tyk2抑制剂ICP-488治疗皮肤性狼疮的二期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2593483856","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483856","media":"时代财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483856?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:58","pubTimestamp":1766393880,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂 JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251222/c673401182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","LU1064130708.USD","688331","LU2148510915.USD","LU2488822045.USD","688235","LU1064131003.USD","688428"],"gpt_icon":0},{"id":"2592134408","title":"港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2592134408","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592134408?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:17","pubTimestamp":1766114258,"startTime":"0","endTime":"0","summary":"消息面上，12月18日，据诺诚健华官微消息，公司宣布，自主研发的新型TYK2抑制剂soficitinib治疗慢性自发性荨麻疹获国家药品监督管理局药品审评中心批准开展II/III期临床试验。Soficitinib是诺诚健华自主研发的高效、高选择性的新型口服TYK2抑制剂，开发用于治疗多种T细胞相关的自身免疫性疾病，目前开发的适应症深度布局皮肤科这一广阔的市场，包括特应性皮炎、白癜风、结节性痒疹、荨麻疹等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK1161","688428","BK4134","BK0239","BK1574","III"],"gpt_icon":0},{"id":"2592201369","title":"奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2592201369","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592201369?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:03","pubTimestamp":1766041380,"startTime":"0","endTime":"0","summary":"12月15日，生物医药公司诺诚健华宣布，其核心产品奥布替尼用于治疗系统性红斑狼疮（SLE）的IIb期临床研究达到主要终点，并已获国家药品监督管理局批准开展Ⅲ期临床试验。这一进展虽标志着该药在开拓自身免疫疾病这一巨大新市场的道路上迈出关键一步，但其通往成功商业化的道路仍布满不确定性，或将面临来自临床试验、市场竞争及公司战略的多重严峻挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595356395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595356395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SLE","BK0239","09969","BK4077","159992","BK1161","688428","06978","BK1574"],"gpt_icon":0},{"id":"1162325715","title":"诺诚健华宣布在中国获批新型Tyk2抑制剂Soficitinib用于慢性自发性荨麻疹的II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1162325715","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162325715?lang=zh_cn&edition=full","pubTime":"2025-12-18 09:50","pubTimestamp":1766022610,"startTime":"0","endTime":"0","summary":"诺诚健华宣布在中国获批新型Tyk2抑制剂Soficitinib用于慢性自发性荨麻疹的II/III期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2591097566","title":"12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591097566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591097566?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:36","pubTimestamp":1765870568,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日诺诚健华跌6.09%，收盘报22.5元，换手率2.81%，成交量7.55万手，成交额1.72亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元，最新净值3.1742，较上一交易日下跌3.71%，近一年上涨34.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600020122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","BK1574","688428","BK0239"],"gpt_icon":0},{"id":"2591565672","title":"创新药概念再度走低 诺诚健华(09969.HK)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591565672","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591565672?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:21","pubTimestamp":1765855266,"startTime":"0","endTime":"0","summary":"每经AI快讯，创新药概念股再度走低，截至发稿，诺诚健华(09969.HK)跌5.09%，报12.86港元；石药集团(01093.HK)跌3.99%，报7.21港元；信达生物(01801.HK)跌3.36%，报79港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163592831521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592831521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","BK1574","06978","09969","159992","BK1161","BK0239"],"gpt_icon":0},{"id":"2591644571","title":"诺诚健华：截至2025年11月28日A股股东户数约1.79万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644571","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591644571?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:43","pubTimestamp":1765806180,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日，诺诚健华在互动平台回答投资者提问时表示，截至2025年11月28日公司A股股东户数约为1.79万户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153592007823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","159982","BK1161","BK0239","688428","BK1574","399300"],"gpt_icon":0},{"id":"1121316255","title":"诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1121316255","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121316255?lang=zh_cn&edition=full","pubTime":"2025-12-14 17:50","pubTimestamp":1765705817,"startTime":"0","endTime":"0","summary":"诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2591665068","title":"诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2591665068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591665068?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:27","pubTimestamp":1765700828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)公告，公司自主研发的BTK抑制剂奥布替尼治疗系统性红斑狼疮(简称“SLE”)的IIb期临床研究达到主要终点，并获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展III期注册性临床试验。公司将尽快启动该临床研究。临床IIb结果展示，在接受治疗48周的患者中，奥布替尼展现了卓越的有效性、良好的耐受性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09969","BK0239","BK1161","688428"],"gpt_icon":0},{"id":"2590257886","title":"港股诺诚健华涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590257886","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590257886?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:21","pubTimestamp":1765520510,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华(09969.HK)涨超3%，截至发稿，涨3.24%，报14港元，成交额5105.45万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512123590068918.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590068918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2590520907","title":"港股异动 | 诺诚健华(09969)涨超3% 预计不久将递交佐来曲替尼治疗儿童患者新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2590520907","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590520907?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:05","pubTimestamp":1765519550,"startTime":"0","endTime":"0","summary":"消息面上，12月11日，诺诚健发布公告，国家药品监督管理局已批准第二代小分子泛原肌球蛋白相关激酶抑制剂佐来曲替尼，用于治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者。佐来曲替尼已被NMPA纳入“星光计划”，该计划是一项为鼓励儿童抗肿瘤药物研发而开展的试点项目。本公司预计不久将递交佐来曲替尼治疗儿童患者的新药上市申请。NTRK融合基因存在于各种类型的肿瘤，目前已在超过26种实体瘤中发现了NTRK融合基因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","09969","688428","BK0239","BK1161"],"gpt_icon":0},{"id":"2589712808","title":"诺诚健华宣布宜诺凯（奥布替尼）新增适应症纳入2025年国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589712808","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589712808?lang=zh_cn&edition=full","pubTime":"2025-12-07 18:07","pubTimestamp":1765102044,"startTime":"0","endTime":"0","summary":"12月7日，2025年《国家基本医疗保险、生育保险和工伤保险药品目录》（国家医保药品目录）在广州正式公布。诺诚健华医药有限公司（以下简称“诺诚健华”）自主研发的布鲁顿酪氨酸激酶（BTK）抑制剂宜诺凯?（奥布替尼）新增适应症被纳入2025年国家医保药品目录，用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584604256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1161","688428","BK0239","BK1574"],"gpt_icon":0},{"id":"2588880472","title":"诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880472?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:20","pubTimestamp":1764858034,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘，诺诚健华报收于24.84元，较前一交易日上涨1.89%，最新总市值为438.34亿元。公司近日发布公告，披露截至2025年11月30日的证券变动月报表。公告显示，诺诚健华医药有限公司法定股本无变动，已发行股份总数保持不变。公司存在股权激励计划，包括2023年及2024年人民币股股份激励计划，部分限制性股票已失效，但本月未发生新股发行或库存股转让。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK0239","688428","BK1161","161027","BK1574"],"gpt_icon":0},{"id":"2587751162","title":"诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2587751162","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587751162?lang=zh_cn&edition=full","pubTime":"2025-11-29 11:36","pubTimestamp":1764387398,"startTime":"0","endTime":"0","summary":"11月28日，诺诚健华医药有限公司（以下简称“诺诚健华”）宣布，公司自主研发的新型TYK2抑制剂Soficitinib（ICP-332）治疗结节性痒疹的全球II期临床试验完成首例患者给药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511293578279828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1574","688428","BK1161","09969"],"gpt_icon":1},{"id":"2586189785","title":"诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586189785","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586189785?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:15","pubTimestamp":1764324916,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问贵公司近两年是否出口欧盟国家？诺诚健华（688428.SH）11月28日在投资者互动平台表示，尊敬的投资者，您好！截至目前，公司暂无自研药品于欧盟范围内获批及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511283577874557.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511283577874557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1161","09969","BK1574","688428"],"gpt_icon":0},{"id":"1169461698","title":"诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症","url":"https://stock-news.laohu8.com/highlight/detail?id=1169461698","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169461698?lang=zh_cn&edition=full","pubTime":"2025-11-28 09:56","pubTimestamp":1764295015,"startTime":"0","endTime":"0","summary":"诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767178015159,"stockEarnings":[{"period":"1week","weight":-0.0708},{"period":"1month","weight":-0.209},{"period":"3month","weight":-0.2781},{"period":"6month","weight":-0.1764},{"period":"1year","weight":0.6225},{"period":"ytd","weight":0.6767}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1456},{"period":"1year","weight":0.1637},{"period":"ytd","weight":0.183}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17900人(较上一季度减少4.79%)","perCapita":"14992股","listingDate":"2022-09-21","address":"Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}